Prognostic role of pretreatment F-18-FDG PET/CT and hematological parameters in relapsed/refractory Hodgkin lymphoma patients treated with immune checkpoint inhibitors and chemotherapy: a dual-center cohort study

作者全名："Yang, Tianyu; Liu, Shuang; Zuo, Rui; Liang, Hongwei; Xu, Lu; Wang, Zhengjie; Chen, Xiaoliang; Pang, Hua"

作者地址："[Yang, Tianyu; Liu, Shuang; Zuo, Rui; Xu, Lu; Wang, Zhengjie; Pang, Hua] Chongqing Med Univ, Affiliated Hosp 1, Dept Nucl Med, Chongqing 400042, Peoples R China; [Liang, Hongwei] Chongqing Med Univ, Affiliated Hosp 1, Dept Radiol, Chongqing 400042, Peoples R China; [Chen, Xiaoliang] Chongqing Univ Canc Hosp, Dept Nucl Med, Chongqing 400030, Peoples R China"

通信作者："Pang, H (通讯作者)，Chongqing Med Univ, Affiliated Hosp 1, Dept Nucl Med, Chongqing 400042, Peoples R China.; Chen, XL (通讯作者)，Chongqing Univ Canc Hosp, Dept Nucl Med, Chongqing 400030, Peoples R China."

来源：BMC MEDICAL IMAGING

ESI学科分类：CLINICAL MEDICINE

WOS号：WOS:000928375400002

JCR分区：Q2

影响因子：2.7

年份：2023

卷号：23

期号：1

开始页：　

结束页：　

文献类型：Article

关键词：Immune checkpoint inhibitors; Chemotherapy; Classical Hodgkin lymphoma; F-18-FDG PET; CT; Prognosis

摘要："BackgroundThe combination of anti-programmed death-1 antibodies and chemotherapy is effective; however, there are no reliable outcome prediction factors. We investigated the prognostic factors based on (18)Fluorine-fluorodeoxyglucose positron emission tomography/computed tomography (F-18-FDG PET/CT) quantitative and hematological parameters to predict progression-free survival (PFS) in relapsed/refractory classical Hodgkin lymphoma (R/R cHL) patients treated with immune checkpoint inhibitors (ICIs) and chemotherapy.MethodsThis retrospective study included 31 patients who underwent F-18-FDG PET/CT before and during treatment. Pretreatment metabolic and hematological parameters were evaluated using Cox regression analysis to identify predictors of PFS. Based on the cut-off values calculated using the receiver operating characteristic (ROC) curve, patients were classified into low-, intermediate-, and high-risk groups. Kaplan-Meier curves and the log-rank test were used to compare survival differences between the groups.ResultsCox multivariable analysis indicted that the treatment response based on Lactate dehydrogenase (LDH), Lugano classification and SUVmax were independent predictors of PFS (P = 0.004, 0.007 and 0.039, respectively). The optimal cut-off values for SUVmax and LDH were 11.62 and 258.5 U/L, respectively (P < 0.01). Survival curves showed that LDH >= 258.5U/L and SUVmax >= 11.62 were correlated to shorter PFS (P < 0.001, P = 0.003, respectively). The differences in PFS between the low-, intermediate-, and high-risk groups were statistically significant (P = 0.0043).ConclusionIn R/R cHL patients treated with ICIs and chemotherapy, Lugano classification, SUVmax, and LDH were significantly correlated with PFS. The combination of metabolic and hematological parameters predicts PFS and may help to improve patient selection."

基金机构：Chongqing medical scientific research project (Joint project of Chongqing Health Commission and Science and Technology Bureau) [2021MSXM087]; Chongqing medical scientific research project [2021MSXM042]; General program of Chongqing Natural Science Foundation [cstc2020jcyj-msxmX0713]

基金资助正文："This work was supported by the Chongqing medical scientific research project (Joint project of Chongqing Health Commission and Science and Technology Bureau) (grant number: 2021MSXM087), Chongqing medical scientific research project (grant number: 2021MSXM042) and General program of Chongqing Natural Science Foundation (grant number: cstc2020jcyj-msxmX0713)."